vs
Cytek Biosciences, Inc.（CTKB）与牛津地产（IIPR）财务数据对比。点击上方公司名可切换其他公司
牛津地产的季度营收约是Cytek Biosciences, Inc.的1.1倍（$66.7M vs $62.1M），牛津地产净利率更高（47.8% vs -70.9%，领先118.7%），Cytek Biosciences, Inc.同比增速更快（8.1% vs -13.1%），过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs -6.0%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
CTKB vs IIPR — 直观对比
营收规模更大
IIPR
是对方的1.1倍
$62.1M
营收增速更快
CTKB
高出21.3%
-13.1%
净利率更高
IIPR
高出118.7%
-70.9%
两年增速更快
CTKB
近两年复合增速
-6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $66.7M |
| 净利润 | $-44.1M | $31.8M |
| 毛利率 | 52.9% | — |
| 营业利润率 | -9.0% | 47.8% |
| 净利率 | -70.9% | 47.8% |
| 营收同比 | 8.1% | -13.1% |
| 净利润同比 | -557.1% | -20.4% |
| 每股收益（稀释后） | — | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBIIPR
| Q4 25 | $62.1M | $66.7M | ||
| Q3 25 | $52.3M | $64.7M | ||
| Q2 25 | $45.6M | $62.9M | ||
| Q1 25 | $41.5M | $71.7M | ||
| Q4 24 | $57.5M | $76.7M | ||
| Q3 24 | $51.5M | $76.5M | ||
| Q2 24 | $46.6M | $79.8M | ||
| Q1 24 | $44.9M | $75.5M |
净利润CTKBIIPR
| Q4 25 | $-44.1M | $31.8M | ||
| Q3 25 | $-5.5M | $29.3M | ||
| Q2 25 | $-5.6M | $26.0M | ||
| Q1 25 | $-11.4M | $31.1M | ||
| Q4 24 | $9.6M | $40.0M | ||
| Q3 24 | $941.0K | $40.2M | ||
| Q2 24 | $-10.4M | $42.0M | ||
| Q1 24 | $-6.2M | $39.4M |
毛利率CTKBIIPR
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
营业利润率CTKBIIPR
| Q4 25 | -9.0% | 47.8% | ||
| Q3 25 | -17.6% | 45.5% | ||
| Q2 25 | -23.3% | 45.9% | ||
| Q1 25 | -36.1% | 47.4% | ||
| Q4 24 | 5.2% | 54.7% | ||
| Q3 24 | -8.2% | 54.8% | ||
| Q2 24 | -18.3% | 53.1% | ||
| Q1 24 | -23.9% | 55.7% |
净利率CTKBIIPR
| Q4 25 | -70.9% | 47.8% | ||
| Q3 25 | -10.5% | 45.3% | ||
| Q2 25 | -12.2% | 41.4% | ||
| Q1 25 | -27.5% | 43.3% | ||
| Q4 24 | 16.8% | 52.2% | ||
| Q3 24 | 1.8% | 52.6% | ||
| Q2 24 | -22.4% | 52.6% | ||
| Q1 24 | -13.8% | 52.3% |
每股收益（稀释后）CTKBIIPR
| Q4 25 | — | $1.07 | ||
| Q3 25 | — | $0.97 | ||
| Q2 25 | — | $0.86 | ||
| Q1 25 | — | $1.03 | ||
| Q4 24 | — | $1.35 | ||
| Q3 24 | — | $1.37 | ||
| Q2 24 | — | $1.44 | ||
| Q1 24 | — | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $47.6M |
| 总债务越低越好 | — | $393.7M |
| 股东权益账面价值 | $341.7M | $1.8B |
| 总资产 | $461.5M | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资CTKBIIPR
| Q4 25 | $90.9M | $47.6M | ||
| Q3 25 | $93.3M | $41.9M | ||
| Q2 25 | $75.5M | $104.9M | ||
| Q1 25 | $95.3M | $133.3M | ||
| Q4 24 | $98.7M | $151.2M | ||
| Q3 24 | $162.3M | $172.4M | ||
| Q2 24 | $177.9M | $160.9M | ||
| Q1 24 | $168.8M | $173.5M |
总债务CTKBIIPR
| Q4 25 | — | $393.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CTKBIIPR
| Q4 25 | $341.7M | $1.8B | ||
| Q3 25 | $378.6M | $1.9B | ||
| Q2 25 | $377.6M | $1.9B | ||
| Q1 25 | $379.6M | $1.9B | ||
| Q4 24 | $395.7M | $1.9B | ||
| Q3 24 | $385.5M | $1.9B | ||
| Q2 24 | $389.1M | $1.9B | ||
| Q1 24 | $392.6M | $2.0B |
总资产CTKBIIPR
| Q4 25 | $461.5M | $2.4B | ||
| Q3 25 | $494.9M | $2.3B | ||
| Q2 25 | $493.3M | $2.3B | ||
| Q1 25 | $482.6M | $2.4B | ||
| Q4 24 | $499.5M | $2.4B | ||
| Q3 24 | $491.2M | $2.4B | ||
| Q2 24 | $483.7M | $2.4B | ||
| Q1 24 | $492.1M | $2.4B |
负债/权益比CTKBIIPR
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $198.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | — |
| 自由现金流率自由现金流/营收 | -2.9% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | — | 6.22× |
| 过去12个月自由现金流最近4个季度 | $-8.8M | — |
8季度趋势，按日历期对齐
经营现金流CTKBIIPR
| Q4 25 | $-771.0K | $198.2M | ||
| Q3 25 | $-3.9M | $45.6M | ||
| Q2 25 | $108.0K | $48.4M | ||
| Q1 25 | $-125.0K | $54.2M | ||
| Q4 24 | $2.0M | $258.4M | ||
| Q3 24 | $13.2M | $64.9M | ||
| Q2 24 | $6.2M | $64.2M | ||
| Q1 24 | $4.0M | $71.6M |
自由现金流CTKBIIPR
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
自由现金流率CTKBIIPR
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
资本支出强度CTKBIIPR
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
现金转化率CTKBIIPR
| Q4 25 | — | 6.22× | ||
| Q3 25 | — | 1.56× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.75× | ||
| Q4 24 | 0.21× | 6.46× | ||
| Q3 24 | 14.05× | 1.61× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
IIPR
暂无分部数据
